Home Newsfeeds Needham Maintains Buy on SPS Commerce, Raises Price Target to $160

Needham Maintains Buy on SPS Commerce, Raises Price Target to $160

Needham analyst Scott Berg maintains SPS Commerce (NASDAQ:SPSC) with a Buy and raises the price target from $150 to $160.

byBenzinga Newsdesk

February 10, 2023

1 minute read

Needham analyst Scott Berg maintains SPS Commerce (NASDAQ:SPSC) with a Buy and raises the price target from $150 to $160.

Bristol Myers’ Opdivo Shows Improved Clinical Benefits In Bladder Cancer At Three Years

By Vandana Singh

February 17, 1:45 PM

Bristol-Myers Squibb Co (NYSE:BMY) announced three-year follow-up results from the Phase 3 CheckMate -274 Phase 3 trial of Opdivo compared to placebo…

BMY

Bally’s Inks B2B Sports Betting Agreements With Kambi And White Hat Gaming To Power “Bally Bet”

By Shivani Kumaresan

May 2, 5:48 AM

Bally’s Corp (NYSE:BALY) has entered into exclusive, multi-year agreements with Kambi Group plc and White Hat Gaming to serve as its B2B online sports betting…

BALY

Nasdaq Moves Higher; US New Home Sales Fall In October

By Lisa Levin

November 27, 1:21 PM

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite moving higher on Monday. The Dow traded down 0.23% to 35,310.40 while the NASDAQ rose 0.21% to 14,280.12. The S&P 500 also fell, dropping, 0.07% to 4,556.10.

ASST

Detailed Data From Gilead Halted Blood Cancer Drug Magrolimab Program Shows Higher Deaths And Side Effects

By Vandana Singh

June 17, 12:19 PM

Gilead's recent data from two Phase 3 trials show higher adverse events and lower transplant rates in patients treated with magrolimab.

GILD

Needham Maintains Buy on SPS Commerce, Raises Price Target to $160

Related Posts

Bristol Myers’ Opdivo Shows Improved Clinical Benefits In Bladder Cancer At Three Years

Bally’s Inks B2B Sports Betting Agreements With Kambi And White Hat Gaming To Power “Bally Bet”

Nasdaq Moves Higher; US New Home Sales Fall In October

Detailed Data From Gilead Halted Blood Cancer Drug Magrolimab Program Shows Higher Deaths And Side Effects